PRODUCT
首頁
產品資訊
PRODUCT
首頁
產品資訊
產品特點
| 編號 | 名稱 | 描述 | 純度 |
| HB6130 | UCPH-102 | Selective EAAT1 inhibitor | >98% |
| HB3732 | 7BIO | Aurora B and C kinase inhibitor | >99% |
| HB0097 | A-7 hydrochloride | Potent, cell-permeable calmodulin (CaM) antagonist | |
| HB1007 | A 803467 | Potent, selective Nav1.8 channel inhibitor | >98% |
| HB3218 | A 83-01 | Selective TGF-βRI (ALK5), ALK4 and ALK7 inhibitor. Maintains human induced pluripotent stem cell (hiPSC) self renewal. | >98% |
| HB1156 | A 967079 | Potent, selective TRPA1 channel blocker | >98% |
| HB2354 | AACOCF3 | Selective cPLA2 inhibitor | |
| HB3599 | 17-AAG | Selective Hsp90 inhibitor. Also protects neuroprogenitor cells against apoptosis. | >98% |
| HB0103 | Acetildenafil | Sildenafil analog | >98% |
| HB1477 | Actinomycin D | RNA polymerase inhibitor | >98% |
| HB3737 | Actinonin | Broad metalloprotease inhibitor | >97% |
| HB1501 | AF-DX 116 | Selective, competitive M2receptor antagonist | >98% |
| HB1424 | AG 490 | Selective EGF receptor tyrosine kinase inhibitor | >99% |
| HB3744 | Agistatin B | Cholesterol biosynthesis inhibitor | >98% |
| HB3745 | Agistatin D | Cholesterol biosynthesis inhibitor. Analog of agistatin A. | >98% |
| HB3747 | AK-7 | Brain-permeable SIRT2 (sirtuin 2) inhibitor | >98% |
| HB3749 | Aloeresin A | α-Glucosidase inhibitor. Aloesin metabolite | >97% |
| HB2038 | α-Bungarotoxin | α7 subtype selective nAChR antagonist | >99% |
| HB1734 | Alprenolol hydrochloride | Non-selective β-adrenoceptor antagonist. Also a 5-HT1Areceptor antagonist. | >99% |
| HB3754 | Alsterpaullone | Potent CDK1 inhibitor. Also shows activity at GSK-3β | >98% |
| HB3755 | Altenusin | Non-competitive, specific neutral sphingomyelinase (N-SMase) inhibitor. | >97% |
| HB2776 | AM251 | Potent, selective CB1 receptor antagonist / inverse agonist | >98% |
| HB1174 | AM 404 | Selective, competitive carrier-mediated anandamide transport inhibitor | >98% |
| HB0109 | Amantadine hydrochloride | Non-competitive NMDA receptor antagonist | >98% |
| HB3757 | Amastatin hydrochloride | Competitive aminopeptidase (AP) inhibitor | >98% |
| HB3758 | Amauromine | Potent and selective CB1 receptor antagonist | >95% |
| HB2739 | AMD 3100 octahydrochloride | Potent, selective CXCR4 antagonist. Mobilizes hematopoietic stem cells. | |
| HB1188 | AMG 9810 | Potent, selective, competitive TRPV1 channel antagonist | >98% |
| HB3761 | Amidepsine A | Diacylglycerol acyltransferase (DGAT) inhibitor | >95% |
| HB3762 | Amidepsine D | Diacylglycerol acyltransferase (DGAT) inhibitor | >95% |
| HB3729 | 6-Amino-8-trifluoromethylphenanthridine | Ribosome-borne protein folding activity (RPFA) inhibitor | >99% |
| HB0111 | Aminoguanidine bicarbonate | NOS inhibitor | >98% |
| HB3730 | 6-Aminophenanthridine | Ribosome-borne protein folding activity (RPFA) inhibitor | >97% |
| HB1879 | Amisulpride | Potent, selective dopamine D2 and D3 receptor antagonist. Atypical antipsychotic. | >98% |
| HB1794 | Amitriptyline hydrochloride | Serotonin/norepinephrine reuptake inhibitor (SNRI) | >99% |
| HB1214 | Amlodipine besylate | L-type calcium channel blocker | >99% |
| HB1167 | AMTB hydrochloride | TRPM8 channel blocker | >99% |
| HB1380 | Anacardic acid | Non-competitive HAT inhibitor | >97% |
| HB3763 | Andrastin A | Protein farnesyltransferase (PFTase) inhibitor | >95% |
| HB1157 | AP 18 | TRPA1 channel antagonist | >98% |
| HB0249 | DL-AP4 | Broad spectrum glutamate antagonist | >98% |
| HB0225 | D-AP5 | Selective, competitive NMDA receptor antagonist | >99% |
| HB0251 | DL-AP5 | Competitive NMDA receptor antagonist | >99% |
| HB0252 | DL-AP5 sodium salt | Competitive NMDA receptor antagonist. Sodium salt. | >98% |
| HB1051 | Apamin | Potent, selective KCa2 channel subfamily inhibitor | |
| HB3690 | (+)-Aphidicolin | DNA polymerase α and δ inhibitor | >98% |
| HB1384 | Apicidin | Potent HDAC inhibitor | >98% |
| HB0117 | Apigenin | PKC inhibitor | >98% |
| HB1258 | AR-A 014418 | Potent, selective GSK3 inhibitor | >99% |
| HB0118 | Arcaine sulfate | Competitive NMDA receptor antagonist / NOS inhibitor | >99% |
| HB0119 | Arctigenin | Potent MAP kinase kinase (MKK/MEK) inhibitor | >98% |
| HB4630 | Arglabin | Farnesyltransferase inhibitor. NF-κB inhibitor | >98% |
| HB1115 | Artemisinin | Plasmodium falciparum SERCA orthologue inhibitor | >99% |
| HB0123 | Ascomycin | Calcineurin phosphatase inhibitor | |
| HB1238 | L-Ascorbic acid | Antioxidant. Enhances iPSC generation and increases reprogramming efficiency. | >99% |
| HB0374 | L-Aspartic acid | Endogenous NMDA receptor agonist | |
| HB3778 | Aspochalasin I | Melanogenesis inhibitor | >95% |
| HB3783 | Atpenin A5 | Potent and specific mitochondrial complex II inhibitor | >95% |
| HB3785 | Aureothin | NADH ubiquinone oxidoreductase inhibitor | >96% |
| HB3786 | Aureothricin | RNA polymerase inhibitor | >98% |
| HB3787 | Aurodox | Type 3 secretion system (T3SS) inhibitor | >95% |
| HB3543 | AY 9944 dihydrochloride | Hedgehog signaling inhibitor. Δ,7-dehydrocholesterol reductase inhibitor. | >99% |
| HB1356 | 5-aza-2’-deoxycytidine (Decitabine) | DNA methyltransferase inhibitor | >99% |
| HB1374 | 5-Azacytidine | DNA methyltransferase inhibitor. Improves stem cell reprogramming efficiency | >98% |
| HB3716 | 1-Azakenpaullone | Potent and ATP-competitive GSK-3β inhibitor | >98% |
| HB1322 | AZM 475271 | Src tyrosine kinase inhibitor | >99% |
| HB1125 | Bafilomycin A1 | Highly potent, selective V-ATPase inhibitor | >98% |
| HB3792 | Bafilomycin C1 | Specific vacuolar-type H+-ATPase inhibitor | >98% |
| HB0129 | Bakuchiol | PTB1B inhibitor | >97% |
| HB3793 | BAY 11-7082 | IκBα kinase and NF-κB inhibitor. | >99% |
| HB1190 | BCTC | Potent, selective TRPV1 channel antagonist | >98% |
| HB1242 | BDS II | Selective, reversible Kv3 channel inhibitor | |
| HB3796 | Becatecarin | Topoisomerase II inhibitor | >98% |
| HB1216 | Benidipine hydrochloride | Ca 2+ channel inhibitor | >99% |
| HB3798 | β-Rubromycin | Telomerase inhibitor | >98% |
| HB1787 | Bicifadine hydrochloride | Potent noradrenalin transporter antagonist. Also 5-HT and dopamine transporter antagonist. | >98% |
| HB0896 | (+)-Bicuculline | Prototypic, competitive GABAA receptor antagonist | >99% |
| HB0893 | (-)-Bicuculline methiodide | Prototypic, competitive GABAA receptor antagonist | >98% |
| HB0894 | (-)-Bicuculline methobromide | Prototypic, competitive GABAA receptor antagonist | >98% |
| HB0895 | (-)-Bicuculline methochloride | Prototypic, competitive GABAA receptor antagonist | >98% |
| HB1259 | BIO | Potent GSK-3α/β inhibitor. Maintains ESC self-renewal and pluripotency. | >98% |
| HB0135 | Bisindolylmaleimide II | Potent PKC inhibitor | >97% |
| HB0136 | Bisindolylmaleimide III | Selective PKC inhibitor | >98% |
| HB0137 | Bisindolylmaleimide IV | Selective, non-competitive PKC / PKA inhibitor | >98% |
| HB2958 | Bisindolylmaleimide IX methansulfonate | Selective, cell permeable PKC inhibitor | >98% |
| HB0138 | Bisindolylmaleimide V | Selective PKC / S6K inhibitor | |
| HB0141 | Bisindolylmaleimide VIII | Potent, selective PKC inhibitor | >98% |
| HB0142 | Bisindolylmaleimide X | Potent, selective PKC inhibitor | |
| HB1413 | BIX 01294 | Potent, selective GLP / G9a HMTase inhibitor. Potentiates iPSC induction. | >98% |
| HB4634 | BLZ-945 | Potent, selective colony stimulating factor 1 receptor (CSF-1R) inhibitor | >95% |
| HB1323 | Bosutinib | Abl / Src kinase inhibitor | >99% |
| HB0144 | bpV(bipy) | Potent protein PTP inhibitor | >95% |
| HB0147 | bpV(pic) | Potent PTP inhibitor | >90% |
| HB3815 | BQ-123 sodium salt | Potent, selective endothelin receptor A (ETA) antagonist | >98% |
| HB3816 | BQ-788 sodium salt | Potent, selective endothelin B receptor (ETBR) antagonist | >95% |
| HB3344 | BRD 7116 | Leukemia stem cell activity inhibitor | >98% |
| HB1666 | BRL 15572 hydrochloride | Selective h5-HT1D antagonist | |
| HB3820 | Butyrolactone I | Potent, selective CDK1, CDK2 and CDK5 inhibitor | >97% |
| HB3822 | Butyrolactone II | 5-Lipoxygenase (5-LOX) inhibitor | >97% |
| HB0150 | BVT 948 | Non-competitive irreversible PTP inhibitor | |
| HB7820 | CA200656 CellAura fluorescent β2 antagonist [(±)-propranolol] | Fluorescent β2 adrenoceptor antagonist | |
| HB7828 | CA200992 CellAura fluorescent 5-HT1A antagonist [NAN-190] | Fluorescent 5-HT1A receptor antagonist | |
| HB2846 | Caffeine | Non-selective, competitive adenosine receptor antagonist / PDE inhibitor | |
| HB0156 | Calmidazolium Chloride | Calmodulin (CaM) antagonist | >98% |
| HB0160 | Calphostin C | Potent, selective PKC inhibitor. Also antagonizes the Tcf/β-catenin complex | >98% |
| HB0162 | CaM Kinase II (290-309), Calmodulin Antagonist | Potent, competitive CaMKII inhibitor | >97% |
| HB0165 | cAMPS-Rp, triethylammonium salt | cAMP antagonist | >98% |
| HB0167 | Cantharidic Acid | Potent, selective PP2A inhibitor | >98% |
| HB1040 | Capsazepine | TRPV1 channel antagonist | >99% |
| HB3824 | Carboplatin | Cisplatin analog. Blocks DNA replication and transcription. | >98% |
| HB3389 | CCG 1423 | Rho/SRF pathway inhibitor. Induces intermediate mesoderm differentiation from ESCs. | >99% |
| HB4605 | Celastrol | Anti-oxidant, anti-inflammatory compound with many actions. Topoisomerase II inhibitor. | >98% |
| HB3826 | Cercosporin | Potent and specific PKC inhibitor | >95% |
| HB4822 | Cesium Gluconate (Cs-Gluc) | Potassium channel blocker. Component in cesium gluconate-based internal solutions used for patch clamp electrophysiology. | |
| HB0179 | CFM-2 | Selective, non-competitive AMPA receptor antagonist | >98% |
| HB0955 | CGP 35348 | Selective GABAB receptor antagonist | |
| HB1132 | CGP 37157 | Potent, selective mitochondria Na+ / Ca2+exchange inhibitor | >99% |
| HB0960 | CGP55845 hydrochloride | Potent, selective GABABreceptor antagonist | >98% |
| HB0186 | CGP 74514A | Selective CDK1 inhibitor | |
| HB1415 | Chaetocin | Potent histone methyltransferase SUV39H1 inhibitor | >99% |
| HB3829 | Chaetoviridin A | Monoamine oxidase (MAO) inhibitor | >96% |
| HB1052 | Charybdotoxin | Potent, selective KCachannel inhibitor | |
| HB0190 | Chelerythrine Chloride | PKC inhibitor | >98% |
| HB1459 | Chetomin | HIF-1 formation inhibitor | >98% |
| HB1261 | CHIR 99021 | Potent, selective GSK3 inhibitor. Wnt signaling activator. | >98% |
| HB1262 | CHIR 99021 trihydrochloride | Potent, selective GSK3 inhibitor. Wnt signaling activator. Water soluble. | >98% |
| HB3834 | Chloroguanabenz acetate | Antiprion compound. Protein aggregation inhibitor. | >95% |
| HB1647 | p-Chlorophenylalanine | Irreversible tryptophan hydroxylase inhibitor. Depletes 5-HT. | >99% |
| HB0988 | Chromanol 293B | Kv7.1 channel blocker | >99% |
| HB3835 | Chrysomycin A | Topoisomerase II inhibitor | >98% |
| HB3836 | Chrysomycin B | Topoisomerase II inhibitor | >98% |
| HB3837 | CHS-828 | IκB kinase inhibitor. NF-κB inhibitor. | >98% |
| HB1385 | CI 994 | Potent, selective HDAC inhibitor | >99% |
| HB1217 | Cilnidipine | Potent L- / N-type calcium channel blocker | >99% |
| HB2142 | Citalopram hydrobromide | Potent, selective 5-HT uptake inhibitor | >99% |
| HB3842 | clasto-Lactacystin β-lactone | Potent, selective and irreversible proteasome inhibitor | >95% |
| HB1974 | (±)-Clopidogrel hydrochloride | Selective, irreversible P2Y12 receptor antagonist | >99% |
| HB0077 | CMIQ | Potent, selective PKA inhibitor | >95% |
| HB2840 | Cmpd101 | Novel, potent and selective GRK2/GRK3 inhibitor | >98% |
| HB0205 | CNQX disodium salt | Potent, competitive AMPA / kainate receptor antagonist. Disodium salt. | >98% |
| HB0204 | CNQX | Potent, competitive AMPA / kainate receptor antagonist | >98% |
| HB1013 | Co 102862 | Potent voltage-gated Na+channel blocker | >99% |
| HB3848 | Compound 34 | Highly potent, cell permeable γ-secretase inhibitor | >98% |
| HB3849 | Compound E | Potent, selective, non-competitive γ-secretase inhibitor | >98% |
| HB3850 | Concanamycin B | Specific vacuolar-type H+-ATPase inhibitor | >98% |
| HB3851 | Concanamycin C | Vacuolar-type H+-ATPase inhibitor | >98% |
| HB1218 | ω-Conotoxin GVIA | Potent, selective Cav2.2 (N-type) channel blocker | >98% |
| HB1219 | ω-Conotoxin MVIIC | N-, P- and Q-type voltage-dependent Ca2+ channel blocker | >99% |
| HB0214 | CP 465022 hydrochloride | Potent, non-competitive AMPA receptor antagonist | >99% |
| HB1427 | CP 690550 citrate | Potent JAK inhibitor | >99% |
| HB0215 | CP-91149 | Synthetic GP inhibitor | |
| HB0021 | (R)-CPP | Potent NMDA receptor antagonist | |
| HB1434 | Cryptotanshinone | STAT3 inhibitor | >98% |
| HB3853 | Curvularin | iNOS inhibitor with many biological actions | >95% |
| HB3854 | Curvulin | Microtubule assembly inhibitor | >98% |
| HB2965 | Cyclopamine | Smo and hedgehog (Hh) signaling inhibitor. Also depletes stem like cancer cells. | >98% |
| HB3857 | Cyclopenin | Specific acetylcholinesterase (AChE) inhibitor. | >98% |
| HB1117 | Cyclopiazonic acid | Potent SERCA1a inhibitor | >98% |
| HB0220 | Cyclosporin A | Potent calcineurin inhibitor. Inhibits MPTP opening. | >99% |
| HB3859 | Cyclosporin C | Calcineurin inhibitor. Immuosuppresant. | >95% |
| HB3860 | Cyclosporin D | Calcineurin inhibitor. Potent inhibitor of tumor promoting phorbol ester (TPA/PMA) effects. | >97% |
| HB3861 | Cyclosporin H | Potent Formyl peptide receptor (FPR) inhibitor | >97% |
| HB0222 | Cypermethrin | Potent PP2B inhibitor | >96% |
| HB1657 | Cyproheptadine hydrochloride | Non-selective 5HT2 antagonist | >98% |
| HB0870 | Cystamine dihydrochloride | Transglutaminase inhibitor | |
| HB3862 | Cytochalasin H | Actin polymerization inhibitor | >98% |
| HB3863 | Cytochalasin J | Actin and myosin inhibitor. | >98% |
| HB3864 | Cytostatin | Potent, selective PP2A inhibitor | >75% |
| HB2167 | D 4476 | TGF-βRI and CK1 inhibitor | >99% |
| HB1404 | Daminozide | Selective KDM2/7 histone demethylase inhibitor | |
| HB1505 | 4-DAMP | Selective M3 receptor antagonist | >99% |
| HB0229 | Daphnetin | Protein kinase inhibitor | >97% |
| HB1788 | Dapoxetine hydrochloride | Selective serotonin reuptake inhibitor (SSRI) | >99% |
| HB3345 | DAPT | γ-secretase inhibitor. Also induces neuronal differentiation. | >98% |
| HB3419 | DBZ | γ-secretase and Notch pathway inhibitor. Stimulates iPSC formation. | >98% |
| HB1416 | 3-Deazaneplanocin A hydrochloride | Histone methyltransferase inhibitor. Enhances Oct4 expression in chemically-induced pluripotent stem cells. | >98% |
| HB3866 | Decarestrictine D | Cholesterol biosynthesis inhibitor | >98% |
| HB3708 | 10,11-Dehydrocurvularin | TGF-β signaling inhibitor | >95% |
| HB3723 | 3-Deoxyaphidicolin | Specific DNA polymerase α inhibitor | >98% |
| HB0070 | 2,4-Diamino-6-hydroxypyrimidine | GTP cyclohydrolase I (GCH1) inhibitor | >98% |
| HB3874 | Dihydrochlamydocin | Phytotoxin. Derivative of the HDAC inhibitor chlamydocin. | >95% |
| HB1611 | Dihydroergocristine mesylate | 5-HT antagonist. Also partial agonist at adrenergic and dopaminergic receptors. | >98% |
| HB1612 | Dihydroergotamine mesylate | Partial α-adrenergic agonist, partial D2agonist and 5-HT antagonist | >98% |
| HB0247 | Dihydrosphingosine | PKC inhibitor | |
| HB3717 | 2,5-Dimethyl-celecoxib | Shows no COX-2 inhibitory function. Analog of celecoxib. | >99% |
| HB1119 | Disulfiram | Reversibly stimulates SERCA Ca2+-ATPase. V-ATPase inhibitor. | |
| HB3110 | DMH-1 | Selective ALK2 inhibitor. Promotes iPSC neurogenesis. | >98% |
| HB0261 | DNQX | Selective, competitive AMPA / kainate receptor antagonist | >98% |
| HB0262 | DNQX disodium salt | Selective, competitive AMPA / kainate receptor antagonist. Sodium salt. | >98% |
| HB1078 | Dofetilide | Selective potassium channel blocker | >99% |
| HB1888 | Domperidone | Peripheral dopamine D2-like receptor antagonist | >99% |
| HB2800 | Dorsomorphin dihydrochloride | Potent, selective AMPK inhibitor. Also promotes cardiomyocyte differentiation in mouse embroynic stem cells (mESCs) | >98% |
| HB2094 | DPCPX | Potent, selective A1 receptor antagonist | >98% |
| HB3878 | DPQ | Highly potent PARP-1 inhibitor | >99% |
| HB1806 | (S)-Duloxetine hydrochloride | Potent 5-HT and NA reuptake inhibitor. Also inhibits dopamine reuptake. | >99% |
| HB1245 | Dynasore | Cell permeable, potent and selective dynamin GTPase inhibitor | >99% |
| HB1080 | E-4031 dihydrochloride | Potent, selective Kv11.1 channel blocker | >98% |
| HB0269 | E6 Berbamine | Potent, selective CaM antagonist | |
| HB0270 | Ebselen | Broad enzyme inhibitor | >98% |
| HB3882 | Echinosporin | G(2)/M phase cell cycle inhibitor | >98% |
| HB3540 | EHNA hydrochloride | Potent adenosine deaminase and PDE2 inhibitor. Supresses spontaneous hESC differentiation. | >98% |
| HB3885 | Elasnin | Leukocyte elastase inhibitor | >98% |
| HB0274 | Eliprodil | Non-competitive, GluN2B subunit selective NMDA receptor antagonist | >98% |
| HB0275 | Ellagic Acid, Dihydrate | Potent CK2 inhibitor | >99% |
| HB4638 | Empagliflozin | Potent, selective sodium glucose co-transporter 2 (SGLT-2) inhibitor | >98% |
| HB3889 | epi-Aszonalenin A | Derivative of aszonalenin, a substance P inhibitor. | >95% |
| HB2527 | Eplerenone | Selective mineralcorticoid receptor antagonist | >99% |
| HB3890 | Epoxomicin | Potent, selective and irreversible 20S proteasome inhibitor | >97% |
| HB0257 | DL-erythro-Dihydrosphingosine | PKC inhibitor | |
| HB0237 | D-erythro-N,N-Dimethylsphingosine | Sphingosine kinase inhibitor | >98% |
| HB0239 | D-erythro-Sphingosine | PKC inhibitor | >98% |